Here is a comprehensive overview of melasma drawn from Fitzpatrick's Dermatology, Dermatology 2-Volume Set 5e, and Andrews' Diseases of the Skin.
Melasma (Chloasma / "Mask of Pregnancy")
Definition & Epidemiology
Melasma is a common acquired disorder of hyperpigmentation characterized by symmetric, irregularly bordered brown patches occurring predominantly on sun-exposed skin, especially the face. Key epidemiologic facts:
-
90% of patients are women
- Most prevalent in Fitzpatrick skin types III-V: Hispanic, East/West/Southeast Asian, Middle Eastern, and Black individuals
- Subtle melasma (by UV light exam) seen in up to 30% of middle-aged Asian women
- Men are also affected, especially those from Central America
- The forearms are the second most common site after the face
Pathogenesis
The exact pathogenesis is not fully understood, but two major triggers are established:
1. UV / Sun Exposure (Primary Trigger)
- Melasma predominantly affects sun-exposed areas and worsens in summer
- Patients have a lower minimal erythema dose (MED) to UV light
- Affected skin shows increased solar elastosis compared to adjacent unaffected facial skin
- Melasma-affected skin has reduced WIF-1 (a Wnt antagonist), leading to increased Wnt signaling, which stimulates melanogenesis
- Number of melanocytic nevi correlates with melasma risk
2. Female Hormones (Second Trigger)
- Melasma occurs frequently during pregnancy, with oral contraceptive (OC) use, and hormone replacement therapy (HRT)
- Discontinuing OCs/HRT rarely clears the pigmentation - it can persist for years
- Melasma of pregnancy typically clears within months of delivery
- Also seen in other endocrinologic disorders and with phenytoin and finasteride therapy
Clinical Features
Morphology: Well-demarcated, tan-to-dark brown patches, sharply demarcated borders
Distribution patterns (3 classic facial types):
| Pattern | Location |
|---|
| Centrofacial (most common) | Forehead, cheeks, upper lip, nose, chin |
| Malar | Cheeks and nose |
| Mandibular | Ramus of mandible |
Most patients have multiple patterns, making classification less useful therapeutically.
Classification by Melanin Location
| Type | Location of Melanin | Wood's Lamp | Response to Treatment |
|---|
| Epidermal | Basal and suprabasal layers | Enhanced (accentuated) | Better |
| Dermal | Within melanophages | Not enhanced | Poor |
| Mixed | Both layers | Variable | Intermediate |
Note: Most cases show both epidermal and dermal melanin on histology and confocal microscopy. Dermal deposits respond poorly to topical agents regardless of Wood's lamp findings - a therapeutic trial should be offered to all patients.
Differential Diagnosis
| Condition | Key Distinguishing Features |
|---|
| Postinflammatory hyperpigmentation | History of inflammation; less irregular outline |
| Drug-induced hyperpigmentation | History of doxycycline, amiodarone, etc.; less patterned |
| Riehl melanosis (pigmented contact dermatitis) | Sites of cosmetic application; brown-grey due to dermal melanin |
| Acquired bilateral nevus of Ota (Horii nevus) | Asian women; brown-grey to blue macules; nasal predominance |
| Lichen planus pigmentosus | Temporal/preauricular onset; coexistent LP in ~20% |
| Exogenous ochronosis | History of HQ use; progressive darkening; banana-shaped yellow-brown deposits on histology |
| Erythema dyschromicum persans | Slate-grey to blue-brown; involves sun-protected areas |
Treatment
Treatment must be multimodal. Results take up to 6 months to appreciate. Recurrence is the norm even with adequate treatment.
Universal Recommendations (All Patients)
- Broad-spectrum sunscreen SPF ≥30 daily (ideally with zinc oxide or titanium dioxide as physical blocker)
- Sun-protective hats and clothing
- Camouflage makeup with iron oxide (blocks visible light, which also drives pigmentation)
- Avoid tanning beds
- Discontinue oral contraceptives if possible
First-Line Topical Therapies
- Triple combination (Kligman's formula): Hydroquinone (HQ) + retinoid (tretinoin) + topical corticosteroid - the most effective topical regimen available
- Use 4% HQ (daily, typically bedtime); OTC formulations contain 2%
- Twice-weekly application is effective for maintenance
- Side effects of overuse: fixed erythema, telangiectasias, acneiform eruptions, hypertrichosis; exogenous ochronosis from HQ overuse
- Typically used daily for 2-4 months, then tapered to 1-2x/week
- Azelaic acid 15-20%
- Tretinoin alone (less effective than HQ but beneficial)
Adjunctive Topical Therapies
- L-ascorbic acid 10-15%
- Kojic acid 1-4%
- Tranexamic acid 2-5%
- Niacinamide 4%
Adjunctive Oral Therapies
- Tranexamic acid 250 mg BID for 8-12 weeks - screen patients for thromboembolic risk factors before use
Second-Line Therapies
- Chemical peels: Glycolic acid (start 30%, increase as tolerated) or salicylic acid (20-30%) every 4-6 weeks
- Peels alone do not reproducibly enhance 4% HQ and can cause hyperpigmentation if irritation occurs
Third-Line Therapies (Procedural)
- Non-ablative fractional laser - improvement in 60% of skin types III-V with 75-100% improvement; may enhance HQ absorption via microscopic channels
- Intense pulsed light (IPL) - can improve melasma but has high relapse rate
- Low-fluence Q-switched lasers - Q-switched Nd:YAG can paradoxically increase pigmentation
- Picosecond lasers
- Er:YAG resurfacing - only temporary improvement, often followed by problematic postinflammatory hyperpigmentation
- Pulsed dye laser - may enhance topical combination treatment
⚠️ All light-based therapies should be approached with caution in darker skin types - complications include hyperpigmentation, hypopigmentation, irritation, and scarring. Always perform a test spot first.
Long-Term Maintenance
- Daily sunscreen + sun protection
- Topical retinoid
- Topical alpha-hydroxy acid (e.g., glycolic acid cream)
- Rotating adjunctive topicals: L-ascorbic acid, azelaic acid, kojic acid, tranexamic acid
Recent Evidence (2024-2025)
A 2025
systematic review on glutathione as a skin-lightening agent in melasma (Sarkar et al.,
Int J Dermatol, 2025; PMID 39444151) evaluated oral and topical glutathione, finding emerging but still limited evidence for its role in melasma management.
Sources: Andrews' Diseases of the Skin, p. 993-994 | Dermatology 2-Volume Set 5e, p. 1343, 2859 | Fitzpatrick's Dermatology